Online Business

Govt urges US regulator not to punish Satyam

India has requested the US Securities Exchange Commission (SEC) not to impose any fine on Mahindra Satyam, formerly Satyam Computer Services Ltd (SCSL), as this will impede the new entity’s rehabilitation. - AOL to lay off one-third of its workforce - Intel to pay AMD $1.25 bn, settle all disputes - SEC shares info with CBI on Satyam scam probe - European Commission objects to $7.4 bn Sun-Oracle deal - Cognizant buys UBS captive unit for $75 mn - ADRs gain $11 bn in September The SEC has been probing the company, which is also listed on the New York Stock Exchange (NYSE), after founder-head Ramalinga Raju disclosed that his company’s accounts had been cooked for years. The scam, according to the Central Bureau of Information (CBI), could be to the tune of Rs 14,000 crore and not Rs 7,800 crore, as claimed by Raju initially. “(Mahindra) Satyam has been put back on its feet. The biggest jolt in the Satyam fraud was to the shareholders and if the SEC imposes a penalty, they will be impacted. It will be a setback to the company, which is in the process of being rehabilitated,” said Salman Khurshid, Union minister for corporate affairs. He was speaking at the sidelines of a conference at the Indian Institute of Social Welfare and Business Management here.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

News of the day
Sensex slips again; realty index down 2%
The Sensex after attempting recovery has once again slipped into the red. The index is now at 16,677, down 108 points. The NSE Nifty is at 4,947, down 42 points.
Popular Articles

Policy review: Banks with funds to emerge winners
India is clearly showing strong growth, as outlined by the RBI which stated that the output gap is narrowing with economy operating close to potential and raised its baseline projection for GDP growth in FY10 to 7.5 per cent from 6 per cent forecast in October 2009 in the monetary policy announced today.

US FDA say GSK vaccine blocks cancer virus
The US Food and Drug Administration says a vaccine from GlaxoSmithKline successfully blocks the virus that causes most cases of cervical cancer.